Biotech Values

[DewDiligence]

YMTX reverse-merges into—(private)—Kineta:

https://finance.yahoo.com/news/yumanity-therapeutics-announces-definitive-agreements-103000748.html

Upon closing of the proposed transaction, Yumanity Therapeutics, Inc. will be renamed Kineta, Inc., and will be headquartered in Seattle, Washington. …current Kineta stockholders are expected to own approximately 85% of the combined company and current Yumanity stockholders are expected to own approximately 15% of the combined company.

…Kineta is a clinical-stage biotechnology company with a mission to develop next generation immunotherapies that transform patients’ lives. Kineta has leveraged its expertise in innate immunity with an intent to develop first or best-in-class immunotherapies that address the major challenges with current cancer therapy.

YMTX is also selling its own pipeline to JNJ for $26M in cash, which will be returned to existing YMTX shareholders as a one-time dividend.

p.s. This is another instance of a double sequential reverse-merger in that YMTX is itself the result of a reverse-merger consummated in 2020 (#msg-157833849).